glp 1 agonists quizlet Understanding GLP-1 GLP-1 Agonists Archives - Penn

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

These assets aim to move beyond the current weekly injection paradigm, signalling a future where extended dosing intervals could become central to maintenance strategies [16].

pooling data for lixisenatide (Adlyxin, Sanofi), liraglutide (Victoza,

One seen as easier: GLP-1 medications. Since the beginning of time, people...

But for complex drugs like this, quality control is still improving